Alicia Morgans, MD, MPH

This episode, titled “Emerging Treatment Strategies in mCSPC,” features panelists discussing the rapidly evolving treatment landscape in metastatic castration-sensitive prostate cancer (mCSPC) and the growing number of therapeutic approaches being incorporated alongside androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs).

In “Risk Stratification and Treatment Intensification Strategies in mCSPC,” our panel explores how clinicians use clinical, molecular, and genomic risk factors to personalize treatment decisions for patients with metastatic castration-sensitive prostate cancer (mCSPC). The expert faculty discuss how disease volume, timing of metastasis, tumor burden, PSA kinetics, and patient comorbidities influence risk stratification and guide the selection of doublet, triplet, and metastasis-directed treatment approaches.

In the final episode, “Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer,” the panelists explored the evolving role of treatment intensification strategies for patients with metastatic castration-sensitive prostate cancer (mCSPC). Using the case of a 63-year-old man with de novo high-volume metastatic disease, the expert faculty discussed how disease burden, patient fitness, comorbidities, and individual treatment goals influence decisions regarding doublet versus triplet therapy.

Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).

Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.

In “Managing High-Risk Biochemical Recurrence in Advanced Prostate Cancer,” our panel explores the evolving treatment landscape for patients experiencing biochemical recurrence following definitive therapy. Through the case of a 75-year-old man with a rising PSA after radical prostatectomy, a rapid PSA doubling time, and multiple cardiovascular and metabolic comorbidities, the expert faculty discuss how risk stratification and patient-specific factors influence treatment selection.

In this episode, “Preserving Quality of Life in Metastatic Castration-Sensitive Prostate Cancer,” the expert faculty explore how cognitive function, independence, and patient priorities influence treatment selection for metastatic castration-sensitive prostate cancer (mCSPC). Through the case of a 74-year-old man with low-volume metastatic disease, mild cognitive impairment, and a strong desire to maintain an active lifestyle, the panel examines the importance of treating the whole patient rather than focusing solely on disease characteristics.

Welcome back to another Urology Times Virtual Tumor Board series. In this episode titled “Navigating Comorbidities and Treatment Decisions in Metastatic Castration-Sensitive Prostate Cancer,” expert faculty discuss a patient with advanced prostate cancer whose management highlights the importance of individualized treatment decisions that extend beyond tumor characteristics alone.

Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.

A real-world analysis found that PSADT was undocumented in most patients with high-risk biochemical recurrence of prostate cancer, potentially delaying treatment initiation and underestimating progression risk.

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

Discover essential strategies for managing advanced prostate cancer, including team collaboration, systematic documentation, and patient care best practices.

Healthcare professionals discuss the growing preference for oral hormone therapy over injectables, emphasizing patient control and comfort in treatment choices.

Experts discuss the cardiovascular risks associated with androgen deprivation therapy, comparing relugolix and leuprolide's impact on coronary plaque formation.

Healthcare professionals discuss the challenges of staff turnover and the importance of communication and systematic notes to ensure patient safety.

Oncologists discuss the importance of guidelines like NCCN and ASCO for navigating cancer treatment complexities and insurance challenges.

Health care professionals discuss the vital role of pharmacy teams in managing complex patient care, emphasizing collaboration and medication safety.

Urologists discuss the importance of monitoring cardiovascular health in patients undergoing androgen deprivation therapy for prostate cancer.

Healthcare professionals discuss strategies to manage cardiovascular risks in cancer patients, emphasizing weight control, exercise, and collaboration with primary care.

Healthcare professionals discuss the importance of addressing quality of life and exercise for patients starting androgen deprivation therapy.

Recent trends show a significant increase in the use of combination therapies for advanced cancer, highlighting the need for ongoing education and adaptation.

Experts discuss the complexities of advanced imaging in cancer diagnosis, highlighting challenges with PET scans and the importance of accurate interpretation.

In this episode, ‘Strategic Use of ADT in mCSPC From Selection to Escalation,’ the multidisciplinary panelists explore the following questions: With multiple generations of ADT now available in advanced prostate cancer, including oral and injectable options, how do you determine which patients are appropriate candidates for which formulation of ADT? When selecting ADT as the backbone for doublet therapy in metastatic castration-sensitive prostate cancer (mCSPC), in which patients do you prefer the oral versus the injectable option? Which androgen receptor pathway inhibitor (ARPI) do you initiate first? Please explain your rationale. In mCSPC, how do you decide when to escalate from ADT–ARPI doublet to triplet therapy, and what patient or disease factors most influence that decision? How do you weigh potential benefits against added toxicity and contraindications? How does cumulative toxicity influence your willingness to escalate therapy or modify treatment plans?

Welcome back to another Urology Times Peer Exchange series. In this episode titled, ‘Treatment Selection in Advanced Prostate Cancer’, Drs. Paul Sieber, Alicia Morgans, Neeraj Agarwal, and Chad Ritch discussed the following question: When developing treatment plans for prostate cancer, what factors influence treatment selection?

Explore the evolving landscape of immunotherapy in prostate cancer, focusing on personalized treatments and innovative combination strategies.

Explore the evolving landscape of prostate cancer treatment, focusing on personalized immunotherapy and effective patient management strategies.

Experts discuss the importance and limitations of real-world evidence in assessing cardiovascular risks associated with ARPIs, emphasizing the need for critical analysis.

Experts discuss the importance of managing cardiovascular health and bone health in prostate cancer treatment, emphasizing real-world data and patient care strategies.

Long-term data on sipuleucel-T reveal significant survival benefits, emphasizing the importance of multiple lines of therapy in patient outcomes.

Experts discuss the importance of early treatment with Provenge for prostate cancer, highlighting patient demographics and response variability.